In last trading session, ImmunoGen Inc. (NASDAQ:IMGN) saw 1.68 million shares changing hands with its beta currently measuring 1.04. Company’s recent per share price level of $5.16 trading at -$0.13 or -2.46% at ring of the bell on the day assigns it a market valuation of $1.12B. That closing price of IMGN’s stock is at a discount of -50.58% from its 52-week high price of $7.77 and is indicating a premium of 39.92% from its 52-week low price of $3.10. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 5.72 million shares which gives us an average trading volume of 3.65 million if we extend that period to 3-months.
ImmunoGen Inc. (NASDAQ:IMGN) trade information
Upright in the red during last session for losing -2.46%, in the last five days IMGN remained trading in the red while hitting it’s week-highest on Monday, 11/21/22 when the stock touched $5.16 price level, adding 3.91% to its value on the day. ImmunoGen Inc.’s shares saw a change of -30.46% in year-to-date performance and have moved -0.58% in past 5-day. ImmunoGen Inc. (NASDAQ:IMGN) showed a performance of -14.71% in past 30-days. Number of shares sold short was 17.72 million shares which calculate 5.09 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $12.50 to the stock, which implies a rise of 58.72% to its current value. Analysts have been projecting $4.00 as a low price target for the stock while placing it at a high target of $22.00. It follows that stock’s current price would drop -326.36% in reaching the projected high whereas dropping to the targeted low would mean a gain of 22.48% for stock’s current value.
ImmunoGen Inc. (IMGN) estimates and forecasts
Statistics highlight that ImmunoGen Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 48.70% of value to its shares in past 6 months, showing an annual growth rate of -35.29% while that of industry is 11.20. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -70.60% in the current quarter and calculating -170.00% decrease in the next quarter. This year revenue growth is estimated to rise 26.40% from the last financial year’s standing.
12 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $20.64 million for the same. And 6 analysts are in estimates of company making revenue of $28.39 million in the next quarter that will end on Mar 2023. Company posted $27.99 million and $38.08 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -26.30% while estimating it to be -25.40% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 5.70% during past 5 years.
ImmunoGen Inc. is more likely to be releasing its next quarterly report between February 23 and February 27 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
ImmunoGen Inc. (NASDAQ:IMGN)’s Major holders
Insiders are in possession of 0.41% of company’s total shares while institution are holding 92.67 percent of that, with stock having share float percentage of 93.05%. Investors also watch the number of corporate investors in a company very closely, which is 92.67% institutions for ImmunoGen Inc. that are currently holding shares of the company. RA Capital Management, L.P. is the top institutional holder at IMGN for having 21.74 million shares of worth $112.19 million. And as of Sep 29, 2022, it was holding 9.85% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 17.45 million shares on Sep 29, 2022. The number of shares represents firm’s hold over 7.90% of outstanding shares, having a total worth of $90.02 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Oct 30, 2022, the former fund manager was holding 11.15 million shares of worth $57.56 million or 5.05% of the total outstanding shares. The later fund manager was in possession of 6.46 million shares on Jun 29, 2022, making its stake of worth around $33.31 million in the company or a holder of 2.92% of company’s stock.